Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry

Abstract Aims The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European Heart Failure M...

Descripció completa

Dades bibliogràfiques

Autors principals:	Uwe Zeymer, Andrew L. Clark, Vivencio Barrios, Thibaud Damy, Jaroslaw Drożdż, Candida Fonseca, Lars H. Lund, Gabriele Di Comite, Stephan Hupfer, Aldo P. Maggioni
Format:	Artigo
Idioma:	Inglês
Publicat:	Oxford University Press 2020-04-01
Col·lecció:	ESC Heart Failure
Matèries:	Sacubitril/valsartan ARNI Heart failure Implementation Heart failure with reduced ejection fraction Real‐life data
Accés en línia:	https://doi.org/10.1002/ehf2.12569
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!